Roger Dailey, MD
Ophthalmic Plastic and Reconstructive Surgery · Portland, ORNPI 1558312835
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 98.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $60,497 and has fallen 93.2% since, to $4,124 in 2025.
Across 92 payments — averaging $1499.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$136K
- AbbVie$777
- Janssen Global Services, LLC$695
- Revance Therapeutics, Inc.$149
Across 6 payments — averaging $27,205 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$163K
What the payments were for
- Consulting fees$79,91258%
- Speaking & faculty fees$44,34032%
- Travel & lodging$10,1217%
- Food & beverage$3,5933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 83 | $136,346 |
| AbbVie(2 entities) | 7 | $777 |
| Janssen Global Services, LLC | 1 | $695 |
| Revance Therapeutics, Inc. | 1 | $149 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 24 | $204 |
| Ciprofloxacin Hcl | 18 | $150 |
| Fluconazole | 18 | $72 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Portland
- Francisco CastilloPortland$59K
- Davin AshrafPortland$9K
- Natalie HoeslyPortland$2K
- Prashanth VallabhanathPortland$1K
- John NgPortland$400
- Eric SteelePortland$24
- Blake FausettEugene$40K
- Vivian SchiedlerAshland$4K
- Tara GoecksBend$2K
- Elizabeth EchalierMedford$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.